Maybe I should say that, generally speaking, in all these trade agreements, and we've experienced this in the past, of course, with some of the FTAs we've signed already—with Colombia and Peru, for example—we don't have the same type of access as maybe the U.S. might have, or others.
Again, the world standard is OIE when it comes down to health regulations. Yet very few countries are following those recommendations. So we see under 21 months in Japan, when really there's no scientific basis for that. We see ractopamine issues in China and Taiwan. Again, it's really not very science-based. Going to under 30 months would allow us to supply year-round, so that would be important.
For many of these countries, having bone-in product, not just boneless, is important, particularly for Korea, where they like bone-in product, for example. This really hampers our ability to trade. Even though you may have trade on the record, meaningful trade or commercial trade simply can't occur.
We like to advise our negotiators to try to get the standards of OIE put into these agreements so that we can actually conduct some meaningful trade.